These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 30919077)

  • 21. Cataract development in patients treated with proton beam therapy for uveal melanoma.
    Seibel I; Cordini D; Hager A; Riechardt AI; Rehak M; Böker A; Böhmer D; Heufelder J; Joussen AM
    Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1625-1630. PubMed ID: 27116211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iris nevi and melanomas: a clinical follow-up study.
    van Klink F; de Keizer RJ; Jager MJ; Kakebeeke-Kemme HM
    Doc Ophthalmol; 1992; 82(1-2):49-55. PubMed ID: 1305027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proton beam therapy for iris melanoma: a review of 15 cases.
    Rundle P; Singh AD; Rennie I
    Eye (Lond); 2007 Jan; 21(1):79-82. PubMed ID: 16410818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iris melanocytic tumours in New Zealand/Aotearoa: presentation, management and outcome in a high UV exposure environment.
    Rapata MEJ; Zhang J; Cunningham WJ; Hadden PW; Patel DV; McGhee CNJ
    Eye (Lond); 2023 Mar; 37(4):692-699. PubMed ID: 35338357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proton therapy for uveal melanoma in 43 juvenile patients: long-term results.
    Petrovic A; Bergin C; Schalenbourg A; Goitein G; Zografos L
    Ophthalmology; 2014 Apr; 121(4):898-904. PubMed ID: 24405742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Local Recurrence After Primary Proton Beam Therapy in Uveal Melanoma: Risk Factors, Retreatment Approaches, and Outcome.
    Seibel I; Cordini D; Rehak M; Hager A; Riechardt AI; Böker A; Heufelder J; Weber A; Gollrad J; Besserer A; Joussen AM
    Am J Ophthalmol; 2015 Oct; 160(4):628-36. PubMed ID: 26133249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trabeculectomy in patients with uveal melanoma after proton beam therapy.
    Riechardt AI; Cordini D; Rehak M; Hager A; Seibel I; Böker A; Gundlach E; Heufelder J; Joussen AM
    Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1379-85. PubMed ID: 26960442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proton Therapy for 166 Patients with Iris Melanoma: Side Effects and Oncologic Outcomes.
    Gollrad J; Böker A; Vitzthum S; Besserer A; Heufelder J; Gauger U; Böhmer D; Budach V; Zeitz O; Joussen AM
    Ophthalmol Retina; 2023 Mar; 7(3):266-274. PubMed ID: 36087876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mortality after diagnosis of small melanocytic lesions of the choroid.
    Lane AM; Egan KM; Kim IK; Gragoudas ES
    Arch Ophthalmol; 2010 Aug; 128(8):996-1000. PubMed ID: 20696999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy.
    Conway RM; Poothullil AM; Daftari IK; Weinberg V; Chung JE; O'Brien JM
    Arch Ophthalmol; 2006 Jun; 124(6):838-43. PubMed ID: 16769837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Ciliary body melanomas. Survival and prognostic aspects after brachytherapy or proton therapy].
    Gambrelle J; Kodjikian L; Rouberol F; Donate D; Duquesne N; Jean-Louis B; Chauvel P; Gérard JP; Romestaing P; Grange JD
    J Fr Ophtalmol; 2004 Jan; 27(1):40-7. PubMed ID: 14968076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Uveal and iridociliary melanomas in young patients : A retrospective analysis of 57 cases].
    Heyer LJ; Metz C; Flühs D; Heyer CM; Bornfeld N
    Ophthalmologe; 2016 Dec; 113(12):1046-1050. PubMed ID: 27286673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Limbal Stem Cell Preservation During Proton Beam Irradiation for Diffuse Iris Melanoma.
    Singh AD; Dupps WJ; Biscotti CV; Suh JH; Lathrop KL; Nairn JP; Shih H
    Cornea; 2017 Jan; 36(1):119-122. PubMed ID: 27755196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.
    Sabazade S; Herrspiegel C; Gill V; Stålhammar G
    BMC Cancer; 2021 Nov; 21(1):1270. PubMed ID: 34819035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proton Beam Irradiation: A Safe Procedure in Postequatorial Extraocular Extension From Uveal Melanoma.
    Seibel I; Riechardt AI; Erb-Eigner K; Böker A; Cordini D; Heufelder J; Joussen AM
    Am J Ophthalmol; 2018 Jul; 191():49-53. PubMed ID: 29655645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diffuse malignant melanoma of the uvea. A clinico-histopathologic study of 39 patients].
    Braun UC; Rummelt VC; Naumann GO
    Klin Monbl Augenheilkd; 1998 Dec; 213(6):331-40. PubMed ID: 10048010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proton beam therapy and iris neovascularisation in uveal melanoma.
    Boyd SR; Gittos A; Richter M; Hungerford JL; Errington RD; Cree IA
    Eye (Lond); 2006 Jul; 20(7):832-6. PubMed ID: 16167079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of uveal melanoma with iodine 125 plaques or proton beam therapy: indications and comparison of local recurrence rates].
    Desjardins L; Lumbroso L; Levy C; Mazal A; Delacroix S; Rosenwald JC; Dendale R; Plancher C; Asselain B
    J Fr Ophtalmol; 2003 Mar; 26(3):269-76. PubMed ID: 12746603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical analysis of tumors of the iris and ciliary body].
    Liu GQ; Wu ZY; Feng GG; Yang HS; Yan JH; Zheng HL
    Zhonghua Yan Ke Za Zhi; 2003 Feb; 39(2):77-80. PubMed ID: 12783684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neovascular glaucoma after proton beam therapy of choroidal melanoma: incidence and risk factors.
    Riechardt AI; Pilger D; Cordini D; Seibel I; Gundlach E; Hager A; Joussen AM
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2263-2269. PubMed ID: 28721444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.